Trade and Other Receivables |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||
| Trade and Other Receivables. | ||||||||||||||||||||||||||||||||||||||||||||||
| Trade and Other Receivables | 6. Trade and Other Receivables
All receivables are considered short-term and due within one year. At June 30, 2026 and December 31, 2025 collaboration receivables consisted of amounts receivable from Lilly. At June 30, 2026 and December 31, 2025 prepayments consisted principally of payments made by the Company for services not yet provided by vendors. As at June 30, 2026 and December 31, 2025 the accrued grant income relating to Rett Syndrome Research Trust (“RSRT”) includes the initial fair value of the warrants issued to RSRT that was accounted for as a reduction of the transaction price. The RSRT agreement is described in Note 14. Other Income. At June 30, 2026 and December 31, 2025 other receivables consisted principally of accrued grant income and deposits. |